Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip
Arrayit's unique microarray platform allows the design, manufacture and distribution of H1N1 chip technology quickly and inexpensively, owing
to the Company's unique and patented contact printing technology, versatile system architecture, and broad customer base. "Our team is able to levera...
Angiomax Will Retain Decision Resources' Proprietary Clinical Gold Standard Status Over Current and New Therapies, Including Recently-Approved Efient, for the Treatment of NSTEMI
...relor, The Medicines Company's cangrelor and GlaxoSmithKline's Arixtra are not expected to achieve a market share as high as that of Angiomax, largely owing
to safety or efficacy concerns."
About the Report
NSTEMI: Finding the Balance between Efficacy and Safety is a DecisionBase 2009 report. ...
Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
... product candidate, Alpharadin (based on radium-223), has
blockbuster potential for treating bone metastases arising from multiple
major cancer types, owing
to its bone-targeting nature, potent efficacy
(therapeutic and palliative) and benign, placebo-like safety profile.
Development of Alpharadin is most ...
Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
...A further primary endpoint showed a reduction in the number of migraine
headache days. This reduction did not reach statistical significance,
to the small number of patients participating in the trial
and, it is thought, because some of the patients suffered a type of
migraine aura that is n...
Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
to Well-Established and Effective Insulin-Based Therapies, Market
Growth Will be Modest Through 2017, According to a New Report from Decision ...
Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
to Safety, Escitalopram Will Remain as the Clinical Gold Standard Treatment, According to a New Report from Decision Resources
WALTHAM, Mass., ...
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
...t-feeding women. Pemetrexed can be genotoxic; sexually mature males are advised not to
father a child during treatment and up to 6 months thereafter. owing
possibility of irreversible infertility, men are advised to seek
counselling on sperm storage before starting treatment. Women of